Kosmos Energy Ltd. Common Shares (DE) vs Organon & Co. Common Stock — how do they compare? Kosmos Energy Ltd. Common Shares (DE) trades at $2.71 (market cap $1.66B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 2.2× Kosmos Energy Ltd. Common Shares (DE)'s market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Kosmos Energy Ltd. Common Shares (DE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kosmos Energy Ltd. Common Shares (DE) for 0 Days and Organon & Co. Common Stock for 0 Days on average.
| KOS | OGN | |
|---|---|---|
Market Cap | $1.66B | $3.62B |
Volume | 7,535,344 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $3.27 | $13.81 |
52-Week Low | $0.87 | $5.70 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.30B | $11.04B |
Dividend Yield | — | 0.58% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kosmos Energy Ltd. is a deepwater oil and gas exploration and production company with operations offshore Ghana, Equatorial Guinea, Mauritania, and Senegal in West Africa.
Read more on KOS →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →